Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

  • Heinz Ludwig*
  • , Thomas Melchardt
  • , Siegfried Sormann
  • , Martin Schreder
  • , Johannes Andel
  • , Bernd Hartmann
  • , Christoph Tinchon
  • , Niklas Zojer
  • , Eberhard Gunsilius
  • , Klaus Podar
  • , Alexander Egle
  • , Wolfgang Willenbacher
  • , Ewald Wöll
  • , Reinhard Ruckser
  • , Boris Bozic
  • , Maria-Theresa Krauth
  • , Andreas Petzer
  • , Clemens Schmitt
  • , Sigrid Machherndl-Spandl
  • , Hermine Agis
  • Michael Fillitz, Song-Yau Wang, August Zabernigg, Stefan Knop, Bruno Paiva, Richard Greil
*Corresponding author for this work

Research output: Journal article (peer-reviewed)Letter/short communication

Abstract

Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.

Original languageEnglish
Pages (from-to)1008-1011
Number of pages4
JournalAmerican Journal of Hematology
Volume99
Issue number5
Early online date29 Feb 2024
DOIs
Publication statusPublished - May 2024

Keywords

  • Lenalidomide/therapeutic use
  • Dexamethasone/therapeutic use
  • Humans
  • Induction Chemotherapy
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Multiple Myeloma/diagnosis

Fingerprint

Dive into the research topics of 'Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this